<DOC>
	<DOC>NCT02628600</DOC>
	<brief_summary>This open-label safety extension study will assess the safety and tolerability of once daily dosing of 590 mg Liposomal Amikacin for Inhalation (LAI) added to a multi-drug regimen in subjects with non-tuberculous mycobacterium (NTM) lung infections due to Mycobacterium avium complex (MAC) who are refractory to therapy in Study INS-212.</brief_summary>
	<brief_title>Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212</brief_title>
	<detailed_description />
	<mesh_term>Amikacin</mesh_term>
	<criteria>Key 1. have successfully completed the Month 6 and End of Treatment visits in Study INS212 2. have not achieved the INS212 protocol definition of culture conversion by Month 6 in Study INS212 OR have experienced a relapse or recurrence by Month 6 in Study INS212. Key 1. achieved culture conversion without relapse or recurrence in the Study INS212 study by Month 6</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>